Marinus Pharmaceuticals (NASDAQ:MRNS) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report released on Wednesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

A number of other analysts have also recently commented on MRNS. Royal Bank of Canada cut their target price on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research report on Friday, October 25th. HC Wainwright reiterated a “neutral” rating and issued a $2.00 price objective on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Jefferies Financial Group restated a “hold” rating and set a $0.50 target price (down from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. LADENBURG THALM/SH SH cut shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th. Finally, TD Cowen reiterated a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Nine research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Price Performance

NASDAQ MRNS opened at $0.29 on Wednesday. The firm’s fifty day moving average price is $0.84 and its 200 day moving average price is $1.20. Marinus Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $11.26. The company has a market capitalization of $15.89 million, a price-to-earnings ratio of -0.12 and a beta of 1.25.

Institutional Trading of Marinus Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Franklin Resources Inc. raised its holdings in Marinus Pharmaceuticals by 34.9% during the third quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock worth $8,483,000 after purchasing an additional 1,219,871 shares in the last quarter. World Investment Advisors LLC acquired a new position in Marinus Pharmaceuticals during the 3rd quarter worth approximately $104,000. Jacobs Levy Equity Management Inc. raised its stake in shares of Marinus Pharmaceuticals by 39.5% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock worth $729,000 after buying an additional 117,255 shares in the last quarter. Suvretta Capital Management LLC lifted its holdings in shares of Marinus Pharmaceuticals by 32.8% in the 3rd quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock valued at $8,930,000 after buying an additional 1,253,901 shares during the period. Finally, GSA Capital Partners LLP boosted its stake in shares of Marinus Pharmaceuticals by 409.4% in the third quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock valued at $1,789,000 after buying an additional 817,050 shares in the last quarter. Hedge funds and other institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.